PCK1 and neoplasm: Ho et al. demonstrated that overexpressing phosphoenolpyruvate carboxykinase 1 in tumor-specific CD4+ and CD8+ T-cells could increase the levels of the glycolytic metabolite phosphoenolpyruvate, thereby enhancing tumor suppression by T-cells and increasing survival time in mice with melanoma [119].